Abstract Library

#2854 A Meta-Analysis of the Accuracy of a Neuroendocrine Tumor mRNA Genomic Biomarker (NETest) in Blood

Introduction: The lack of an accurate blood biomarker in neuroendocrine tumor (NET) disease impedes effective management.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Oberg K

Authors: Öberg K, Califano A, Strosberg J, Ma S, Pape U,

Keywords: NETest, Meta-analysis, biomarker, in vitro diagnostic, diagnostic, management, NET, AUC, ROC,

#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest

Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Bodei L

Authors: Bodei L, Kidd M, Singh A, van der Zwan W, Severi S,

Keywords: biomarker, PRRT, prediction, NETest, PPQ, CgA, personalized medicine,

#2836 Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Neoplasms: ENETS Center of Excellence Experience

Introduction: There is a substantial clinical unmet need for an accurate blood biomarker for neuroendocrine neoplasms (NENs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Malczewska A

Authors: Malczewska A, Witkowska M, Wojcik-Giertuga M, Bocian A, Walter A,

Keywords: NETest, liquid biopsy, neuroendocrine, GEP-NEN, BPNEN, CgA, biomarker,

#2220 Validation of a Blood-Based Biomarker Test for the Diagnosis and Management of Bronchopulmonary Neuroendocrine Tumors

Introduction: There is currently no effective blood biomarker for lung neuroendocrine neoplasia diagnosis and management.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Modlin I

Authors: Modlin I, Kidd M, Lewczuk-Myślińska A, Chung K, Ćwikła J,

Keywords: bronchopulmonary, lung, biomarker, PCR, diagnostics, progression,

#1893 Peripheral Blood Biomarkers of Systemic Inflammation May Be Prognostic in Metastatic Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) Patients Following 177Lu-DOTATATE (LuTate)

Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Hayes A, Hosking E, Thomas D, Sjoquist K, Chan D,

Keywords: prognostic, biomarker, PRRT, LuTate,